Ticagrelor doubts: inaccuracies uncovered in key studies for AstraZeneca’s billion dollar drug
Year: 2025
Type: article
Abstract: As generic versions of AstraZeneca’s blockbuster drug ticagrelor prepare to enter the market, The BMJ raises fresh concerns over the integrity of the clinical trials that underpinned its approval. Peter Doshi reports
Source: BMJ
DOI: 10.1136/bmj.r1201
Author: Peter Doshi
Institution: BMJ Group (United Kingdom)
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4411440288